Literature DB >> 19699648

Quality study of a lung cancer committee: study of agreement between preoperative and pathological staging.

Ivan Macia1, Juan Moya, Ignacio Escobar, Ricard Ramos, Cristina Masuet, Cristina Gamez, Roger Llatjos, Ignacio Martinez-Ballarin.   

Abstract

OBJECTIVE: Accurate preoperative staging is essential to provide the best treatment for lung cancer. The objective of the present study was to determine agreement between preoperative and surgical-pathological staging and to analyse the impact of any disparity on treatment.
METHODS: This is a descriptive study of a series of 176 lung cancer cases treated by surgery between 2005 and 2007. Preoperative staging was based on clinical information and computed tomography (CT), positron emission tomography (PET), PET-CT, bronchoscopy and mediastinoscopy. In all cases, surgical-pathological staging was based on the analysis of surgical samples and the findings during surgery. Both preoperative and pathological stage determination were based on the TNM (tumour, node, metastasis) classification established in 1997. Concordance was measured by calculating agreement rates and the kappa value.
RESULTS: Preoperative and surgical-pathological staging agreed in 102 cases, an agreement rate of 58% and kappa value of 0.54 (95% confidence interval (CI) 0.44-0.63). The highest kappa value (0.68, 95% CI 0.53-0.82) was obtained in stage IA patients. Patients who underwent PET or PET-CT had a better kappa index (0.56, 95% CI 0.45-0.67, vs 0.39, 95% CI 0.21-0.56). Surgical-pathological staging validated surgery in 145 cases (82%), while 21 (12%) were revised to stage IIIA N2 and 10 (6%) to non-surgical stages.
CONCLUSIONS: Global agreement between preoperative and surgical-pathological staging was moderate. The best agreement was found in stages IV and IA. Copyright (c) 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19699648     DOI: 10.1016/j.ejcts.2009.07.026

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  2 in total

Review 1.  Clinical staging of NSCLC: current evidence and implications for adjuvant chemotherapy.

Authors:  David J Heineman; Johannes M Daniels; Wilhelmina H Schreurs
Journal:  Ther Adv Med Oncol       Date:  2017-08-02       Impact factor: 8.168

2.  New insights into spectral histopathology: infrared-based scoring of tumour aggressiveness of squamous cell lung carcinomas.

Authors:  Vincent Gaydou; Myriam Polette; Cyril Gobinet; Claire Kileztky; Jean-François Angiboust; Philippe Birembaut; Vincent Vuiblet; Olivier Piot
Journal:  Chem Sci       Date:  2019-03-05       Impact factor: 9.825

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.